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Transarterial chemoembolisation of liver tumours is typically followed by elevated body temperature and liver transaminase enzymes.
This has often been considered to indicate successful embolisation. The present study questions whether this syndrome reflects
damage to tumour cells or to the normal hepatic tissue. The responses to 256 embolisations undertaken in 145 patients subdivided
into those with hepatocyte-derived (primary hepatocellular carcinoma) and nonhepatocyte-derived tumours (secondary metastases)
were analysed to assess the relative effects of tumour necrosis and damage to normal hepatocytes in each group. Cytolysis, measured
by elevated alanine aminotransferase, was detected in 85% of patients, and there was no difference in the abnormalities in liver
function tests measured between the two groups. Furthermore, cytolysis was associated with a higher rate of postprocedure
symptoms and side effects, and elevated temperature was associated with a worse survival on univariate analysis. Multivariate analysis
demonstrated that there was no benefit in terms of survival from having elevated temperature or cytolysis following embolisation.
Cytolysis after chemoembolisation is probably due to damage to normal hepatocytes. Temperature changes may reflect tumour
necrosis or necrosis of the healthy tissue. There is no evidence that either a postchemoembolisation fever or cytolysis is associated
with an enhanced tumour response or improved long-term survival in patients with primary or secondary liver cancer.
British Journal of Cancer (2003) 89, 1423–1427. doi:10.1038/sj.bjc.6601329 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: hepatic artery chemoembolisation; adriamycin; lipiodol; hepatocyte injury; hepatic neoplasms
                                             
The majority of primary and secondary liver cancers are not
treatable by surgical resection due to their advanced stage at
presentation (Famer et al, 1994). Transarterial chemoembolisation
(TACE) of liver tumours is a technique that has been developed for
the treatment of liver tumours. The goal of treatment may be to
downstage a tumour such that resection or transplantation might
be possible, or to provide palliation for unresectable or multifocal
tumours (Higuchi et al, 1994; Lehnert and Herfarth, 1996; Harada
et al, 1996). The technique allows delivery of chemotherapy and
embolic material to either a part of the liver or to the whole liver,
and can be used in conjunction with other embolic agents to limit
the exposure of the body as a whole to chemotherapy, thereby
reducing toxicity. Treatment can be repeated a number of times to
attempt to achieve tumour response. Almost all protocols for
TACE result in a characteristic syndrome following embolisation,
which occurs between 40 and 85% of the patients (Hwang et al,
1987; Lin et al, 1988; Bismuth et al, 1992; Groupe d’Etude de la
traitment du Carcinome Hepatocellulaire, 1995; Takenaka et al,
1995; Chung et al, 1996; Lu et al, 1999). The syndrome is
characterised by a swinging fever, right upper quadrant pain,
elevation of the hepatic transaminase enzymes, aspartate amino
transferase, alanine amino transferase and gamma glutamyl
transferase. The significance of this syndrome is uncertain, but
has been considered by some to represent tumour necrosis and a
successful response to chemoembolisation (Hwang et al, 1987;
Bismuth et al, 1992; Groupe d’Etude de la traitment du Carcinome
Hepatocellulaire, 1995; Castells et al, 1995; Takenaka et al, 1995).
This assertion has been brought into question by a recent study
in which the livers of patients who had undergone TACE prior to
surgical resection of primary hepatocellular carcinoma were
examined (Paye et al, 1999). This study found that the presence
of a chemoembolisation syndrome was not indicative of tumour
necrosis and might indeed represent liver cell damage. One
limiting factor for the above report was that all patients studied
had primary hepatocellular carcinoma. Transaminase enzymes are
produced by normal hepatocytes, but also by cells that have
undergone malignant transformation. The elevation of serum
concentrations of these enzymes following TACE could equally
represent damage to normal hepatocytes, or hepatocytes that have
undergone malignant transformation.
The present study addresses the question of whether the
component of the chemoembolisation syndrome, known as
cytolysis, which is manifested by elevation of hepatic transami-
nases, represents injury to normal hepatocytes or tumour necrosis,
by examining patients who have undergone TACE for hepatocyte-
derived (primary hepatocellular carcinoma) and nonhepatocyte-
derived tumours (metastatic). In addition, the association with the
clinical side effects of TACE and the prognostic significance of the
postchemoembolisation syndrome is studied both in terms of
tumour responses and survival. Received 31 March 2003; accepted 21 July 2003
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lMATERIALS AND METHODS
Patients
Between 1988 and 1998, 145 patients underwent TACE for primary
and secondary liver tumours at the Royal Infirmary of Edinburgh.
Data were collected prospectively on these patients by a dedicated
data manager. Patients were then followed for a minimum of 3
years. Survival data on these patients are complete.
Technique of TACE
Prior to the procedure, each patient received 1g cefotaxime
intravenously. Preliminary angiography (coeliac axis, superior
mesenteric artery and selective studies of the hepatic arteries) was
performed in order to visualise the hepatic arterial anatomy, portal
vein patency and the presence of any arteriovenous shunts.
Angiography was carried out using a 7F gauge superior mesenteric
or sidewinder catheter (Cordis Europa NV). The artery (or
arteries) supplying the tumour area was selectively catheterised.
Where selective delivery of chemotherapeutic agents could not be
achieved using a standard angiographic catheter, a Tracker 3 F
gauge catheter system (William Cook, UK) was used. A standard
dose of 40mg of adriamycin (doxorubicin) was delivered in
combination with the oily medium Lipiodol, the two agents being
mixed together prior to injection. In general, a volume of 10ml of
lipiodol was used, but, with large hypervascular lesions, an
additional 5–10ml of lipiodol was used. Following delivery of
the chemotherapeutic agents, a particulate embolising agent,
Contour (Merck Pharmaceuticals, UK), or Spongstan (Johnson &
Johnson Medical Ltd, Skipton, UK) was introduced into the
tumour-feeding vessels, in order to slow or occlude the flow to the
treated area. Where tumour extent and anatomy permitted, all sites
were treated in one session. Where there was extensive bilobar
disease, one lobe was treated at each session. Repeat chemoembo-
lisations were repeated at 3 monthly intervals and follow-up
computer tomography (CT) scans obtained at 6–8 weeks following
each procedure. Repeat chemoembolisation was not usually
carried out where there was progressive extrahepatic disease,
portal vein invasion or general deterioration of the patient.
Assessment of tumour response
Tumour size was measured by the product of the two largest
perpendicular diameters. Decrease in tumour size was defined as a
greater than 25% reduction in the sum of the products of the
largest perpendicular diameters of all lesions on CT scanning, and
static disease as less than 25% change in measurable lesions for at
least 2 months. Increase in the size of lesions or the development
of new hepatic metastases was considered as the progression of
disease.
For the purposes of this study, we have used the same definition
of the postchemoembolisation syndrome as that by Paye et al
(1999), that is, a rise in temperature of 38.51C or more or an
increase in alanine amino transferase (ALT) of more than 100Ul
 1
and more than double the preprocedural value. We have avoided
the use of postprocedural pain or nausea to define the syndrome,
since these factors are more subjective and less easy to define.
Statistical analysis
Results are presented as medians and ranges unless otherwise
stated. Comparisons between nonparametric data were performed
using the Mann–Whitney U-test or Pearson w
2 test, with
continuity correction as appropriate. Survival curves were plotted
using the Kaplan–Meier plots and one-way comparisons of
survival were performed using the log-rank test. A multivariate
analysis was performed for survival, based on responses to the first
episode of chemoembolisation. This analysis was performed using
a Cox proportional hazards model using a linear regression
function. The time function was survival and this was censored.
Covariates entered into the model were age (continuous), alkaline
phosphatase (4240Uml
 1), elevated ALT (4100Uml
 1), bilir-
ubin (mmoll
 1), albumin falling below 35gl
 1, temperature
(438.51C) and the CT response of the tumour, classified as
increase or new lesions, static, decrease or too unwell to be
assessed (all entered as categorical variables). All statistical
analysis was performed using SPSS 11.0, (Chicago, IL, USA).
RESULTS
Patient characteristics
The study population comprised 101 men and 44 women of
median age 63 (30–82) years. The primary pathology was
hepatocellular carcinoma in 75 patients (52%). All the remaining
patients had metastatic secondary carcinoma confined to the liver.
The most common primary site was the colon and rectum (52
patients). Cirrhosis was present in 58 patients (40%). The majority
of these patients were those with hepatocellular carcinoma (55
patients; 95% of those with cirrhosis). There were two patients
with Child-Pugh grade B cirrhosis, the remainder were all
classified as Child-Pugh grade A.
Technical aspects of TACE
All patients had a patent portal vein, and thus were eligible for
TACE. Selective cannulation of the hepatic arterial branch
supplying the liver was achieved in 228 embolisations (89%); in
the remaining patients, the catheter was positioned in the common
hepatic artery distal to the ostium of the gastroduodenal artery.
Doxorubicin (adriamycin) 40mg mixed with lipiodol 10–20ml
was delivered in 238 procedures (93%), with 20mg being delivered
in the remainder. The reason for using a lower dose in certain
individuals was documented toxicity to this drug during the
previous TACE.
Responses to chemoembolisation
Elevation of temperature above 37.01C occurred following TACE in
89% patients, and 41% of the patients developed a fever diagnostic
of the postchemoembolisation syndrome (438.51C) (Table 1).
Elevation of transaminases occurred following TACE in 93% of
patients. There were other disturbances in serum biochemistry,
evident with a fall in albumin of 5gl
 1, which corrected to normal
values in majority of the patients within 1 week. Bilirubin
increased slightly and International Normalised Ratio (INR) also
increased, suggesting that TACE may have compromised the
hepatic synthetic capacity (Table 1).
Table 1 Biochemical and temperature responses to transarterial
chemoembolisation in 256 embolisations undertaken in 145 patients
Pre Post Change P
Albumin 39 34  5 0.0001
Aspartate aminotransferase 30 227 +158 0.0001
Alkaline phosphatase 153 182 +15 0.0001
Bilirubin 11 21 +11 0.0001
Prothrombin ratio 1.0 1.1 0 0.0001
Temperature 36.8 38.5 +1.7 0.0001
Results are expressed as medians, and statistical comparison between groups was
performed using the Mann–Whitney U-test.
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and nonhepatocyte-derived tumours
The magnitude of the responses to chemoembolisation in patients,
based on the nature of the primary tumour, is shown in Table 2.
Patients with hepatocyte-derived hepatocellular carcinomas had a
higher bilirubin and prothrombin ratio compared to those who
had nonhepatocyte-derived carcinomas (secondary tumours).
There was, however, no significant difference in the magnitude
of the changes in response to chemoembolisation depending on
the tumour type.
Does response to chemoembolisation predict symptoms?
Specific symptoms attributed to chemoembolisation were reported
by 57 patients. These were most commonly nausea and vomiting
or pain. There was no relationship between postchemoembolisa-
tion syndrome and the frequency of postprocedure complications;
however, there was an increased frequency of complications in
patients who had evidence of cytolysis (Pearson w
2 with continuity
correction¼4.218, d.f.¼1, P¼0.04).
Does the occurrence of postchemoembolisation syndrome
or the presence of cytolysis predict either tumour response
or outcome following chemoembolisation?
Neither the postchemoembolisation syndrome (log rank¼1.582,
d.f.¼3, P¼0.663) nor cytolysis (log rank¼2.86, d.f.¼3, P¼0.41)
was associated with improved tumour response, based on CT
assessment 8 weeks following chemoembolisation. Survival analy-
sis demonstrated that the presence of postchemoembolisation
syndrome was associated with an adverse outcome (log
rank¼7.16, d.f.¼1, P¼0.0076) (Figure 1a). The presence of
cytolysis had no effect on outcome (Figure 1b).
When subgroup analysis was performed, the presence of
postchemoembolisation syndrome in those with primary liver
tumours was associated with a poorer survival (median survival
6.8 months, range 4.7–9 months) compared to those without the
syndrome (median survival 12 months, range 7.6–16.5 months)
(log rank¼4.44, d.f.¼1, Po0.04). There was no significant
difference in those with secondary tumours. Analysis of noncir-
rhotic patients with postchemoembolisation syndrome showed a
poorer survival (median survival 8.2 months, range 7.9–8.5
months) compared to those without the syndrome (median
survival 14 months, range 7.4–20.7 months) (log rank¼4.6,
d.f.¼1, Po0.04). There was no significant difference in cirrhotic
patients.
Using a Cox Proportional Hazards model, univariate and
multivariate analysis of a number of factors was undertaken to
assess their individual and combined impact on survival following
the first episode of chemoembolisation. High bilirubin, alkaline
phosphatase, temperature, low albumin, increasing age and a poor
CT response to chemoembolisation were all associated with an
adverse survival, on the basis of univariate analysis (Table 3).
When multivariate analysis was performed, however, only age, low
postprocedural albumin (o35gl
 1) and tumour response to CT
scan remained significant. The response of the tumour based on
CT scanning had the most significant effect and predicted outcome
most accurately (Figure 2).
Table 2 Biochemical and temperature responses to transarterial chemoembolisation in patients with primary hepatocellular carcinoma 125 embolisations
undertaken in 75 patients and secondary carcinoma 131 embolizations performed in 70 patients
Overall change Hepatocellular carcinoma change Secondary carcinoma change P
Albumin  5(  12–5)  5(  15–+5)  5(  13–2) NS
Aspartate aminotransferase 153 ( 8–2309) +151 (33–1423) +188 (8–1717) NS
Alkaline phosphatase 15 ( 123–800) +7.5 (335–1176) NS
Bilirubin 12 (0–116) +13 ( 5–+116) +10 ( 5–123) NS
INR 0 ( 0.1–0.5) +0.1 ( 0.2–+1.1) 0 ( 0.1–4) NS
Temperature 1.6 (0–3.2) +1.8 (0–3.2) +1.6 (0–3.4) NS
Results are expressed as medians and ranges, and statistical comparison between groups was performed using the Mann–Whitney U-test, NS¼not significant.
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Figure 1 Survival curves of patients depending on (A) the presence or
absence of postchemoembolisation syndrome (temperature 438.51C, log
rank¼7.16, d.f.¼1, P¼0.0076) and (B) cytolysis (increase of serum AST
of 4100U and more than 2  prechemoembolisation value, log
rank¼0.2, d.f.¼1, P¼0.65).
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As a treatment modality, TACE retains a useful role in treating
patients with primary or metastatic cancer, which is confined to
the liver but which may not be suitable for resection or
transplantation. It has been used as a primary therapy to try and
downstage tumours prior to surgery and also in a palliative
context. The prediction of who will benefit from this treatment and
how to assess the response to it is rather more difficult. Between 40
and 85% of patients undergoing chemoembolisation experience a
syndrome characterised by elevation of temperature and abdom-
inal pain. These symptoms are typically associated with elevation
of the hepatic transaminases. Recent evidence has suggested that
some of the elements of this syndrome may be associated with
damage to normal liver parenchyma rather than reflecting the
conventional view that this was a representation of tumour damage
and necrosis. For this reason, questions have been raised as to
whether the postchemoembolisation syndrome represents a
beneficial or an adverse response.
Paye et al (1999) examined the association between biochemical
and temperature changes in patients undergoing preoperative
chemoembolisation and pathological findings on subsequent
resection specimens. They found that postchemoembolisation
cytolysis with or without fever was more likely to develop in
patients with minor fibrosis of the liver compared with those who
had obvious cirrhosis. Furthermore, they found that the extent of
tumour necrosis did not correlate with the development of
postchemoembolisation syndrome. Their interpretation of these
data was that cytolysis following chemoembolisation represented
damage to normal hepatocytes. All of the patients in that study had
hepatocellular carcinoma and necrosis of these cells might
contribute to elevation of transaminases following chemoemboli-
sation. The present study has therefore compared responses to
chemoembolisation in patients with both hepatocyte-derived
(primary hepatocellular carcinoma) and nonhepatocyte-derived
tumours (secondary hepatic metastases). In the present study, it
was found that the pattern and the magnitude of changes in
biochemical variables and temperature were not significantly
different, depending on the type of tumour. Thus, when
chemoembolisation is undertaken for tumours that are not derived
from hepatocytes, elevation in transaminases must represent
damage to normal hepatocytes. This study supports earlier studies
(Lin et al, 1988) by demonstrating that the magnitude of damage to
normal liver cells is related to the procedure rather than the
tumour type.
Next we investigated whether there was a correlation between
symptoms described by patients and the presence of cytolysis or
temperature changes. There was no association between tempera-
ture elevation and symptoms; however, patients who experienced
cytolysis had a higher incidence of postprocedure symptoms. It is
possible that this may in part reflect damage to the normal liver
tissue.
Finally, the relationship between postchemoembolisation
syndrome and cytolysis and survival was studied. High
temperature was associated with an adverse outcome on
univariate analysis, although this effect became nonsignificant
when other factors were considered in a multivariate model.
Cytolysis had no bearing on survival in either univariate or
multivariate analyses.
The postchemoembolisation syndrome may be an inevitable
consequence of embolisation of an artery, which may supply both
tumour and normal liver tissue. Our policy has been to attempt the
most selective cannulation of the hepatic artery possible, with the
goal of reducing collateral damage to normal liver. Even after
adopting such a policy and achieving selective hepatic artery
cannulation in 89% of procedures, our patients still had a cytolysis
rate of 93% and elevation of temperature 438.51C in 41% of the
patients. These rates are as high as other studies that have not
adopted selective hepatic artery cannulation, and have delivered
embolic material distal to the ostium of the gastroduodenal artery
(Paye et al, 1998). There is a real danger of causing irreversible
biliary damage through chemoembolisation and many series
present other complications directly attributable to arterial
occlusion.
It is our impression that the postchemoembolisation syndrome
and cytolysis are certainly not associated with a good response of
the tumour and do not predict improved survival. While there is
no conclusive evidence that they are associated with a worse
survival, it is possible that if cytolysis is a result of damage to
normal hepatocytes this may be a detrimental effect, and could
perhaps reduce the ability of patients to tolerate multiple
chemoembolic procedures.
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